6月9日沪指上涨0.43%，盘后龙虎榜数据显示，机构现身21只个股龙虎榜，净买入11只，净卖出10只。 深沪股通席位出现在10只个股龙虎榜。 证券时报·数据宝统计显示，6月9日机构专用席位现身21只个股龙虎榜，合计净买入1.47亿元。个股来 看，净买入11只，净卖出10只。 机构龙虎榜净买卖个股 机构专用席位净买入金额最多的是跨境通，该股今日收盘涨停，全天换手率为34.75%，成交额为23.96 亿元。因日涨幅偏离值达9.07%上榜龙虎榜，前五大买卖营业部中有3家机构专用席位，为买一、买 二、买五，合计净买入22750.82万元。资金流向方面，该股全天资金净流入8.65亿元。 热景生物，今日收盘上涨18.15%，全天换手率为6.41%，成交额为9.02亿元。因日收盘价涨幅达18.15% 上榜龙虎榜，前五大买卖营业部中有4家机构专用席位，为买一、买四、买五、卖二，合计净买入 11003.41万元。资金流向方面，该股全天资金净流入5174.91万元。 常山药业，今日收盘涨停，全天换手率为7.75%，成交额为35.32亿元。因日收盘价涨幅达20.00%上榜龙 虎榜，前五大买卖营业部中有4家机构专用席位，为买二、买五 ...

Group 1 - Company Gongchuang Turf (605099.SH) stated that the impact of domestic football events on its operations and performance is minimal, as its main business of artificial turf has a low revenue contribution from domestic sports grass [1] - Company Anglikang (002940.SZ) confirmed that its innovative drug project ALK-N001 is still in Phase I clinical trials, indicating a long R&D cycle and significant investment [2] - Company Yiwei Lithium Energy (300014.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image [3] Group 2 - Company Chaohongji (002345.SZ) also intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and improve competitiveness [4] - Company Dexin Technology (603032.SH) clarified that its subsidiary's sales revenue from products used in solid-state battery production is less than 1% of total revenue, emphasizing its focus on quality service [5] - Company Changshan Pharmaceutical (300255.SZ) announced that its application for the marketing authorization of Aibennapeptide injection for type 2 diabetes has been accepted, but the approval timeline remains uncertain [6] Group 3 - Company Baili Electric (600468.SH) reported that its revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue [7] - Company Chutianlong (003040.SZ) is exploring digital currency projects but faces risks related to new technology development and commercial application [8] - Company Dongxing Medical (301290.SZ) signed contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan, enhancing its R&D capabilities [9] Group 4 - Company Maixinlin (688685.SH) announced that its subsidiary signed contracts for computing power services worth 1.184 billion yuan, expected to positively impact future performance [10] - Company Haichen Pharmaceutical (300584.SZ) reported that its solid-state battery-related business has not yet generated revenue, which does not significantly affect overall performance [11] - Company Filinger (603226.SH) is undergoing stock trading suspension for investigation due to significant price deviations from fundamentals [12] Group 5 - Company Zhongdian Port (001287.SZ) disclosed that the National Integrated Circuit Fund reduced its stake by 1%, now holding 8.97% of the company [13] - Company Huasheng Co., Ltd. (600156.SH) is planning to acquire 100% of Yixin Technology, leading to a stock suspension for up to 10 trading days [14] - Company Jianghuai Automobile reported a 3.52% year-on-year decline in May sales, with new energy vehicle sales down 57.81% [15] - Company Aonong Biological reported a 9.44% year-on-year increase in May pig sales, with a total of 156,200 pigs sold [16]

6月9日，化学制品、医疗服务、生物制品、中药、医药商业多个板块联动效应明显。概念板块中，减肥 药、创新药、阿兹海默、肝素概念集体飘红，引发市场对医药行业基本面的广泛关注。 中国金融智库特邀研究员余丰慧向《证券日报》记者表示，这主要受到几方面因素的驱动。首先，全球 对医疗健康产品和服务的需求持续增长；其次，各国政府加大对医药行业的政策支持和资金投入，推动 了创新药物的研发和市场准入；再者，人口老龄化的加剧以及慢性病发病率的上升，增加了对医药产品 的长期需求。此外，技术进步如生物技术的发展也为医药行业带来了新的增长点。 据披露，此次三生制药与辉瑞就该款药物的授权协议总额高达60.5亿美元，已经打破了此前国产创新药 产品出海创下的纪录。 此外，采访中，记者了解到，2025年医药行业正迎来"价值重塑期"。国内药企通过license-out(对外许可) 模式深度融入全球产业链，技术授权交易日益频繁。以江苏恒瑞医药（600276）股份有限公司、信达生 物制药(苏州)有限公司为代表的头部企业，凭借创新管线在海外临床及商业化合作中取得关键突破，推 动板块估值中枢持续上移。 细分领域中，创新药无疑是最近二级市场的关注焦点。日前 ...

金十数据6月9日讯，常山药业6月9日公告，股票连续两个交易日收盘价格涨幅偏离值累计超过30%，根 据深圳证券交易所的相关规定，属于股票交易异常波动的情况。自2025年5月6日至6月9日期间，公司股 价累计涨幅达147.69%，已经严重偏离同行业和创业板综合指数增长幅度。公司艾本那肽注射液用于治 疗2型糖尿病的上市许可申请已经获得国家药监局受理，目前处于专业审评阶段，艾本那肽注射液上市 审评后续环节仍然较多，艾本那肽最终能否获批上市及获批时间仍存在不确定性。公司艾本那肽注射液 拟用于减重适应症的临床试验申请已经获得国家药监局受理，目前处于审评阶段，能否获得临床试验批 准通知书存在不确定性。 常山药业：艾本那肽注射液处于审评阶段，能否获批存在不确定性 ...

Core Viewpoint - Changshan Pharmaceutical's application for the marketing authorization of Abemaciclib injection for type 2 diabetes has been accepted, but there is uncertainty regarding its approval and timeline [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative increase of 147.69% from May 6 to June 9, which is over 30% deviation from the industry and ChiNext index growth [1] Group 2: Product Development - The application for clinical trials of Abemaciclib injection for weight loss indications has also been accepted, but there is uncertainty about receiving the approval notice [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-28 河北常山生化药业股份有限公司 4．公司 2024 年度营业收入为 103,081.05 万元，较上年下降 26.92%；归属于上 市公司股东的净利润为亏损 24,947.77 万元；基本每股收益为亏损 0.27 元/股。具体 情况详见公司 2025 年 4 月 29 日于巨潮资讯网站发布的《2024 年年度报告》（公告编 号 2025-11），并请关注其中详述公司经营所面临的风险。 股票交易异常波动公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1．河北常山生化药业股份有限公司（以下简称"公司"）股票连续两个交易日 （2025 年 6 月 6 日、2025 年 6 月 9 日）收盘价格涨幅偏离值累计超过 30%，根据深 圳证券交易所相关规定，属于股票交易异常波动的情况。自 2025 年 5 月 6 日至 6 月 9 日期间，公司股价累计涨幅达 147.69%，已经严重偏离同行业和创业板综合指数增 长幅度，存在市场情绪过热的情形，可能存在非理性交易行为，公司股价可能存在 ...

Group 1 - The A-share market's innovative drug concept stocks have shown strong performance, with the innovative drug sector index reaching a historical high [1] - Notable individual stock performances include Xinghao Pharmaceutical rising over 25%, RuiZhi Pharmaceutical hitting a 20% limit up, and Changshan Pharmaceutical reaching a historical high [1][2] - The overall pharmaceutical sector has experienced a prolonged adjustment period, resulting in low valuations and underweight public holdings, indicating potential for recovery and structural opportunities [2] Group 2 - Specific stock performances include: - Xinghao Pharmaceutical: 25.82% increase, market cap of 3.045 billion [2] - RuiZhi Pharmaceutical: 19.98% increase, market cap of 5.801 billion [2] - Changshan Pharmaceutical: 19.97% increase, market cap of 47.9 billion [2] - Shutaishen: 12.12% increase, market cap of 15.6 billion [2] - The report from China Galaxy Securities suggests that the pharmaceutical market is expected to see continuous recovery and that innovative drug companies will benefit from policy support and improved payment conditions by 2025 [2]

Core Viewpoint - Changshan Pharmaceutical's stock price has surged nearly 200% over the past two months, reaching a historical high, despite the company's operational challenges and reliance on heparin products [1][3]. Company Performance - In 2024, Changshan Pharmaceutical reported a revenue of 1.031 billion yuan, a year-on-year decline of 26.92%, while the net profit attributable to shareholders was -249 million yuan, reflecting a 79.88% reduction in losses [4]. - The company's revenue is heavily dependent on heparin products, which account for nearly 87% of total income, indicating a lack of diversification in its product portfolio [4]. Product Development - The company is in the process of registering its innovative drug, Aibennate Injection, which is a GLP-1 receptor agonist for treating type 2 diabetes, but it is not the first of its kind in the industry [3]. - Aibennate Injection is currently in the registration phase and has not yet been launched for sale. The company faces significant market competition risks even if the product is approved [3]. - The clinical trial application for Aibennate Injection for weight loss indications has been accepted by the National Medical Products Administration, but there is uncertainty regarding the approval and subsequent trial outcomes [3].

Market Overview - On June 6, the Shanghai Composite Index rose by 0.04%, while the Shenzhen Component Index fell by 0.19%, and the ChiNext Index decreased by 0.45% [2] - A total of 54 stocks appeared on the daily trading list due to unusual trading activity, with the highest net inflow of funds into China Electric Power Xinlong (002298.SZ) amounting to 236 million yuan [2] Stock Performance - China Electric Power Xinlong saw a closing price increase of 9.96% with a turnover rate of 19.42%, while Snowman Co., Ltd. (002639.SZ) experienced a net outflow of 210 million yuan and closed down by 1.23% with a turnover rate of 46.27% [2] - Among the 54 stocks, 34 were net bought, and 20 were net sold, indicating a general preference for buying [2] Institutional Activity - On June 6, 26 stocks on the trading list had institutional participation, with a total net purchase of 439 million yuan, where institutions net bought 16 stocks and net sold 10 stocks [2] - The stock with the highest institutional net purchase was Xiongdi Technology (300546.SZ), which closed down by 10.56% with a turnover rate of 47.82% [3] Northbound Capital - Northbound capital participated in 16 stocks on the trading list, with a total net purchase of 304 million yuan, including a net purchase of 54.65 million yuan from the Shanghai Stock Connect and 249 million yuan from the Shenzhen Stock Connect [6] - The stock with the highest net purchase from northbound capital was Changshan Pharmaceutical (300255.SZ), amounting to 202 million yuan, while Snowman Co., Ltd. had the highest net sell of 107 million yuan [6] Common Trends - Both institutions and northbound capital collectively net bought stocks such as Changshan Pharmaceutical, Hailian Jinhui, Hengbao Co., Ltd., Haoshanghao, Maiwei Biotechnology, and Hunan Development [7] - There was a divergence in the trading of Cambridge Technology (603083.SH) and Zhongchong Co., Ltd., with institutions net buying Zhongchong Co., Ltd. while northbound capital net sold it [7]

Group 1 - The A-share innovative drug concept has experienced a volatile rebound, with Changshan Pharmaceutical rising over 16% to reach a historical high [1] - Lianhua Technology increased by more than 9%, indicating positive market sentiment towards innovative drug companies [1] - Other companies such as Anglikang, Sailun Bio, Wanbangde, and Zhongsheng Pharmaceutical also saw gains, reflecting a broader trend in the sector [1]